Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q2 FY26 results · Jul–Sep 2025
Cohance Lifesciences reported revenue from operations of ₹555.57 crore (up 115.6% from Q2 FY25) and net profit of ₹66.39 crore (down 19.0% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 555.57 | 257.72 | +115.6% | 549.31 | +1.1% |
| Other income | 15.60 | 14.12 | +10.5% | 14.17 | +10.1% |
| Total income | 571.17 | 271.84 | +110.1% | 563.48 | +1.4% |
| Profit before tax | 83.77 | 99.50 | −15.8% | 62.76 | +33.5% |
| Net profit for the period | 66.39 | 81.98 | −19.0% | 46.40 | +43.1% |
| Attributable to shareholders of the company | 74.08 | 82.21 | −9.9% | 48.88 | +51.6% |
| EPS, basic (₹) | 1.94 | 3.23 | not comparable | 1.28 | +51.6% |
| Net margin (%) | 11.9 | 31.8 | 8.4 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 497.79 | 236.06 | +110.9% | 483.58 | +2.9% |
| Other income | 26.30 | 13.43 | +95.8% | 13.10 | +100.8% |
| Total income | 524.09 | 249.49 | +110.1% | 496.68 | +5.5% |
| Profit before tax | 120.72 | 100.68 | +19.9% | 71.04 | +69.9% |
| Net profit for the period | 94.29 | 76.33 | +23.5% | 52.57 | +79.4% |
| EPS, basic (₹) | 2.46 | 3.00 | not comparable | 1.38 | +78.3% |
| Net margin (%) | 18.9 | 32.3 | 10.9 |
Consolidated
- Filed with BSE
- 17 Jul 2026, 15:03 IST
- Board meeting
- 12 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Jul 2026, 15:03 IST
- Board meeting
- 12 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE